Report of Foreign Issuer (6-k)
November 29 2016 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2016
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant's name into English)
37 Dereh Menechem Begin St., 15
th
Floor
Tel Aviv 6522042 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
This Report of Foreign Private Issuer on
Form 6-K of the Registrant consists of the press release issued by the Registrant on November 29, 2016, announcing the Registrant’s
financial results for the third quarter ended September 30, 2016, which is attached hereto as Exhibit 99.1.
The first sentence of both the second
and third bullet points under the section titled “Key Corporate Highlights” and the GAAP financial statements in
the press release attached to this Form 6-K of the Registrant are incorporated by reference into the registration statement
on Form F-3 (File No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the
Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit No.
|
99.1
|
Press
Release issued by Bioblast Pharma Ltd. on November 29, 2016, announcing its financial results for the third quarter ended September
30, 3016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Bioblast Pharma Ltd.
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Chaime Orlev
|
|
|
Name: Chaime Orlev
Title: Chief Financial Officer
|
Date: November 29, 2016
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Apr 2023 to Apr 2024